3.85%C 7.22 11.94%GE 17.61 13.61%
The Global Business News Leader | Tuesday, 2 Dec 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- INVESTING
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
OREXIGEN THERAPEUTICS INC.
OREX (NASDAQ)
$ 6.13 
Change: +0.59 +9.62% | Volume: 126,129
Change: +0.59 +9.62% | Volume: 126,129
Sponsored by 
OREXIGEN THERAP - Fundamental Profile
Company Information
| Ticker Symbol: | OREX |
|---|---|
| Exchange: | NASD |
| Contact Info: | |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company\'s lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company\'s understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. |
Share Information
| Shares Outstanding: | 34,320 (000) | Market Value: | 239,910 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 69.62% | Number of Inst.Shareholders: | 44.20% |
| Last Quarter Sales: | 0.02 ($Mil.) | Last Quarter Net Income: | -24.79 ($Mil.) |
| Last Quarter EPS: | -0.72 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -2.84 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Most Popular 
OREX
Companies
IBT
- Oil tumbles below $50 as recession called
- Ahead of the Bell: Construction Spending
- Ahead of the Bell: St. Jude Medical
- '12 Days of Christmas' items would cost $86,609
- Ford weighs selling Volvo amid industry downturn
- Ford says CEO will work for $1 to get gov't loans
- Manufacturing index drops to 26-year low
- U.S. Stocks Tumble into the Red Zone in Afternoon Trade
- U.S. Stocks Gain on Potential Auto Bailout
- U.S. Stocks Dive Ahead of Economic Reports; Ford, GM Gain
- USD/JPY - 93.68 Daily Market Outlook - Dec 1
- JPY Rallies of Safe-Haven Flows
- Vales shares may decrease 1 Pct on Bovespas index by 2009
- Toyota Group to start importing rare-earth metals from India, Vietnam
Top Competitors
| AMGEN INC. |  |
+5.60 | 55.54 |
| GILEAD SCIENCES |  |
-9.90 | 44.79 |
| CELGENE CORPORA | |
-21.80 | 52.10 |
| STEMCELLS INC. | |
-52.80 | 1.06 |
| GENENTECH INC | |
-3.20 | 76.60 |
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives